• Age 18 to 75 years old, gender is not limited.

• ECOG performance status 0-1.

• non-small cell lung cancer diagnosed by pathology.

• sufficient tumor tissue available for biomarker analysis.

• clinical staging of cT1-2N1-2M0 or T3N1M0, stage II-IIIA (8th UICC staging criteria).

• Patients with distant metastases ruled out by CT or PET/CT and physically assessed as acceptable for radical lung cancer surgery.

• histomolecular pathology confirming the absence of classic driver oncogene mutations in EGFR, ALK, or ROS1.

• Basic normal function of all organs (laboratory test results within 1 week prior to enrollment).

‣ Bone marrow function: absolute neutrophil count (ANC) ≥ 1.5x109 /L, platelet count ≥ 100x109 /L, hemoglobin ≥ 9g/dL.

⁃ Liver: serum total bilirubin ≤ 1.5 times the upper limit of normal; ALT and AST ≤ 2.5 times the upper limit of normal.

⁃ Kidney: blood creatinine level ≤ 1.5 times the upper limit of normal or creatinine clearance ≥ 60 ml/min and urea nitrogen ≤ 200 mg/L.

⁃ Urine protein \<+, if urine protein + then total 24 hour protein must be \<500mg.

⁃ Blood glucose: within normal range and/or with diabetic patients on treatment but with stable blood glucose control.

⁃ Pulmonary function: baseline FEV1 of at least 2L; if baseline FEV1 \< 2L then FEV1 \> 800ml is expected after surgery as assessed by a surgical specialist.

⁃ Cardiac function: no myocardial infarction within 1 year; no unstable angina; no symptomatic severe arrhythmia; no cardiac insufficiency.

• Voluntarily participated in this study and signed the informed consent form by himself or his agent